symbol,statement_type,period_end,line_item,value
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Free Cash Flow,15282000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Repayment Of Debt,-49491000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Issuance Of Debt,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Issuance Of Capital Stock,1412000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Capital Expenditure,-187868000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,End Cash Position,17516000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,1000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Beginning Cash Position,41958000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Changes In Cash,-24443000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Financing Cash Flow,-78424000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Other Financing Charges,
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Interest Paid Cff,-168544000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Cash Dividends Paid,-19105000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Common Stock Issuance,1412000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Common Stock Issuance,1412000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Issuance Payments Of Debt,107813000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Short Term Debt Issuance,157304000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Long Term Debt Issuance,-49491000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Long Term Debt Payments,-49491000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Long Term Debt Issuance,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Investing Cash Flow,-149169000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Other Investing Changes,
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Interest Received Cfi,7364000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Investment Purchase And Sale,31325000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Business Purchase And Sale,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Purchase Of Business,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net PPE Purchase And Sale,-187868000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Sale Of PPE,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Purchase Of PPE,-187868000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Operating Cash Flow,203150000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Taxes Refund Paid,-20771000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Working Capital,-74893000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Liabilities,-6123000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Assets,-38093000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Payable,41666000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Inventory,-152109000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Receivables,71844000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Other Non Cash Items,147661000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Stock Based Compensation,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Provisionand Write Offof Assets,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Depreciation And Amortization,97709000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Amortization Cash Flow,
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Depreciation,97709000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,2068000.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Sale Of PPE,0.0
BALPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Income From Continuing Operations,51374000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Free Cash Flow,118258000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Repayment Of Debt,
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Issuance Of Debt,58263000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Issuance Of Capital Stock,5012000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Capital Expenditure,-109800000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,End Cash Position,41958000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,1000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Beginning Cash Position,14871000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Changes In Cash,27086000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Financing Cash Flow,-12063000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Other Financing Charges,2000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Interest Paid Cff,-163263000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Cash Dividends Paid,-15690000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Common Stock Issuance,5012000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Common Stock Issuance,5012000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Issuance Payments Of Debt,161876000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Short Term Debt Issuance,103613000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Long Term Debt Issuance,58263000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Long Term Debt Payments,
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Long Term Debt Issuance,58263000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Investing Cash Flow,-188909000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Other Investing Changes,
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Interest Received Cfi,6886000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Investment Purchase And Sale,-86114000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Business Purchase And Sale,0.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Purchase Of Business,0.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net PPE Purchase And Sale,-109681000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Sale Of PPE,119000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Purchase Of PPE,-109800000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Operating Cash Flow,228058000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Taxes Refund Paid,-45432000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Working Capital,-40428000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Liabilities,-7201000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Assets,10390000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Payable,-5951000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Inventory,101936000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Receivables,-142932000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Other Non Cash Items,140266000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Stock Based Compensation,0.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Provisionand Write Offof Assets,1930000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Depreciation And Amortization,100711000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Amortization Cash Flow,39204000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Depreciation,100711000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,-10353000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Sale Of PPE,-826000.0
BALPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Income From Continuing Operations,90473000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Free Cash Flow,-161825000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Repayment Of Debt,
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Issuance Of Debt,117021000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Issuance Of Capital Stock,39171000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Capital Expenditure,-146454000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,End Cash Position,14871000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,1000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Beginning Cash Position,11127000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Changes In Cash,3743000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Financing Cash Flow,240938000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Other Financing Charges,4798000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Interest Paid Cff,-136834000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Cash Dividends Paid,-15572000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Common Stock Issuance,39171000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Common Stock Issuance,39171000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Issuance Payments Of Debt,354173000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Short Term Debt Issuance,237152000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Long Term Debt Issuance,117021000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Long Term Debt Payments,
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Long Term Debt Issuance,117021000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Investing Cash Flow,-221824000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Other Investing Changes,-1000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Interest Received Cfi,1401000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Investment Purchase And Sale,-8101000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Business Purchase And Sale,0.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Purchase Of Business,0.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net PPE Purchase And Sale,-146454000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Sale Of PPE,
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Purchase Of PPE,-146454000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Operating Cash Flow,-15371000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Taxes Refund Paid,-5044000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Working Capital,-275250000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Liabilities,106525000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Assets,-21826000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Payable,271733000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Inventory,-236094000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Receivables,-398421000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Other Non Cash Items,116269000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Stock Based Compensation,0.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Provisionand Write Offof Assets,1820000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Depreciation And Amortization,91283000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Amortization Cash Flow,19677000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Depreciation,71606000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,8194000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Sale Of PPE,-299000.0
BALPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Income From Continuing Operations,47485000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Free Cash Flow,183262000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Repayment Of Debt,
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Issuance Of Debt,30813000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Issuance Of Capital Stock,9128000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Capital Expenditure,-84693000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,End Cash Position,11126000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,-1000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Beginning Cash Position,10235000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Effect Of Exchange Rate Changes,0.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Changes In Cash,892000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Financing Cash Flow,-172215000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Other Financing Charges,1000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Interest Paid Cff,-104036000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Cash Dividends Paid,-14822000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Common Stock Issuance,9128000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Common Stock Issuance,9128000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Issuance Payments Of Debt,-62486000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Short Term Debt Issuance,-93299000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Long Term Debt Issuance,30813000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Long Term Debt Payments,
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Long Term Debt Issuance,30813000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Investing Cash Flow,-94848000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Other Investing Changes,
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Interest Received Cfi,1787000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Investment Purchase And Sale,-11942000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Business Purchase And Sale,0.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Purchase Of Business,0.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net PPE Purchase And Sale,-84693000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Sale Of PPE,0.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Purchase Of PPE,-84693000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Operating Cash Flow,267955000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Taxes Refund Paid,-12018000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Working Capital,16609000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Liabilities,14477000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Assets,18242000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Payable,205936000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Inventory,-140103000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Receivables,-89359000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Other Non Cash Items,77158000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Stock Based Compensation,0.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Provisionand Write Offof Assets,1588000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Depreciation And Amortization,90401000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Amortization Cash Flow,14684000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Depreciation,75717000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,-6129000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Sale Of PPE,-12336000.0
BALPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Income From Continuing Operations,91825000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Free Cash Flow,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Repayment Of Debt,-36637000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Issuance Of Debt,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Issuance Of Capital Stock,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Capital Expenditure,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,End Cash Position,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Beginning Cash Position,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Effect Of Exchange Rate Changes,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Changes In Cash,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Financing Cash Flow,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Other Financing Charges,37086000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Interest Paid Cff,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Cash Dividends Paid,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Common Stock Issuance,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Common Stock Issuance,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Issuance Payments Of Debt,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Short Term Debt Issuance,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Long Term Debt Issuance,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Long Term Debt Payments,-36637000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Long Term Debt Issuance,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Investing Cash Flow,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Other Investing Changes,281000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Interest Received Cfi,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Investment Purchase And Sale,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Business Purchase And Sale,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Purchase Of Business,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net PPE Purchase And Sale,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Sale Of PPE,210000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Purchase Of PPE,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Operating Cash Flow,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Taxes Refund Paid,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Working Capital,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Liabilities,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Assets,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Payable,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Inventory,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Receivables,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Other Non Cash Items,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Stock Based Compensation,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Provisionand Write Offof Assets,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Depreciation And Amortization,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Amortization Cash Flow,11850000.0
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Depreciation,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Sale Of PPE,
BALPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Income From Continuing Operations,
